License Submission Checklist for Platelets, Leukocytes Reduced Collected by Pheresis
|
|
- Alexia Gallagher
- 6 years ago
- Views:
Transcription
1 License Submission Checklist for Platelets, Leukocytes Reduced Collected by Pheresis Purpose: To provide guidance when submitting documentation to FDA in support of a BLA or a license supplement. Definitions and Abbreviations... 2 Cover Letter... 3 Labeling Requirements... 4 General Chemistry, Manufacturing and Controls... 5 Critical Control Points for Platelets Pheresis Leukocytes Reduced... 8 Reporting Changes to an Approved BLA Product Submission to CBER for Platelets Pheresis Leukocytes Reduced Sterile Connecting Device Miscellaneous Information Version 2, January
2 Definitions and Abbreviations The table below lists the abbreviations that are used throughout this document. Abbreviation/Term Definition BLA Biologics License Application CBE Supplement Changes being effected (30 days waived) CBE 30 Supplement Changes being effected in 30 days CBER Center for Biologics Evaluation and Research Collection Site Fixed or mobile location that collects the pheresis product CMC Chemistry, Manufacturing and Controls Form 2567 Transmittal of Labels and Circulars Form 356h Application to Market a New Drug, Biologic or an Antibiotic Drug for Human Use Infrequent Plasmapheresis Every four weeks or less frequently IQ Installation Qualification OQ Operational Qualification PAS Prior Approval Supplement PQ Performance Qualification STCD Sterile Connecting Device Version 2, January
3 Cover Letter FDA continues to encourage applicants to use a cover letter to introduce and summarize the application. It is recommended that the following topics be covered in the cover letter to the FDA for license submission: Statement/purpose of submission included in first paragraph Full facility name, FDA registration and license numbers Product(s) requested for licensure Manufacturing site(s) or area(s) affected and their CFN/FEI (includes off-site donor or QC testing) Collection device(s) in use at the blood center(s) (only those associated with the products included in the license submission) Anticoagulant used Description of operator s training List of all attachments included in the submission Contact information for questions, concerns or requests for additional information Statement clarifying whether this is the facility s comparability protocol for use with future submissions Note: The Form FDA 356h should be included with each submission to FDA relating to a BLA. It is the cover sheet that allows proper identification, routing and filing of the attached information. Examples of how to complete Form FDA 356h are: Product Description indicate see cover letter for established and chemical name; refer to COI for indications; all else in this section is N/A. Application Description check the BLA and CMC boxes; we check PAS or CBE-30 boxes appropriately. Briefly describe the reason for the submission, e.g., Prior Approval submission for Platelets, Pheresis using the Amicus cell separator. Establishment Information indicate see cover letter. Cross-references list any applicable previously approval STNs/approval dates or applicable Comparability Protocol STNs/approval dates. Page 2 of the 356h check boxes 4, 4A, and 20 ( see cover letter ). To obtain the FDA form, go to Instructions for completing Form FDA 356h are found in Guidance for Industry for the Submission of Chemistry, Manufacturing and Controls and Establishment Description Information for Human Blood and Blood Components Intended for Transfusion or for Further Manufacture and for the Completion of the form FDA 356h Application to Market a New Drug, Biologic or an Antibiotic Drug for Human Use. The guidance can be obtained at Version 2, January
4 Labeling Requirements Each label submitted for review should be submitted with the items listed below. SOP/ Policy # Reference to Prior Submission Items Required for Licensure Attachment # If a label has been previously approved and is to be used without change, do not submit for another review. Instead, reference the label review number to identify the previously approved label. One copy of the current Circular of Information that includes the facility identification information. One original and one copy (labeling set) of each label. (Indicate if it is a printer s proof or final printed labeling for the product). A single Form FDA 2567, completed and signed by an authorized official, should accompany each label set and/or Circular of Information that is submitted for review. Completed Form FDA 3674, Certification of Compliance, under 42 U.S.C. 282(j)(5)(B), with Requirements of ClinicalTrials.gov Data Bank (42 U.S.C. 282(j)) Note: Labels and Form FDA 2567 should be detached from the rest of the submission. The FDA form can be obtained at Apheresis must be indicated on the label in the product name or attributes. Consult the FDA guidance document, Recognition and Use of a Standard for Uniform Blood and Blood Component Container Labels - Sep 2006, Guideline for the Uniform Labeling of Blood and Blood Components Aug 1985, and/or consult the FDA Consumer Safety Officer who will perform the review of your submitted labels. Version 2, January
5 General Chemistry, Manufacturing and Controls The table below lists the common CMC contents for blood products collected by apheresis that should be submitted, or referenced from prior FDA submissions, for all apheresis blood product license submissions. The products may be leukoreduced or nonleukoreduced. The table does not include requirements for additional products collected, including concurrent plasma. Note: Listing of applicable SOPs may be substituted if SOPs have been previously submitted and approved and there will be no significant changes. Ensure that data on submitted records are complete, acceptable and documented as reviewed. SOP/ Policy # Reference to prior submission Items Required for Licensure Attachment # Standard Operating Procedures SOP that describes donor suitability requirement (donor selection) and donor educational material (pre-donation). SOP that describes the donor consent process. SOP that describes the collection of the product for which license is being requested. SOP that describes donor deferral procedure on red cell and plasma loss. SOP that describes the management of donor and receipt complications and reactions (adverse events). SOP that addresses Medical Director review of charts. SOP that describes product acceptability (needs to be consistent with device operator s manual) and failure investigation. SOP that describes the handling of the products (components), to include processing, testing, storage and leukoreduction procedures when appropriate. SOP that describes the quarantine of potentially unsuitable products and subsequent evaluation and disposition. Version 2, January
6 SOP/ Policy # Reference to Prior Submission Items Required for Licensure Attachment # SOP that describes the labeling process for the product to include the method to accurately track multiple units collected from each donation (as needed). SOP that describes packing instructions for the shipment and distribution of the product. SOP that describes the quality control on the product and failure investigation. SOP that describes Equipment QC/ Preventive Maintenance (include cleaning) SOP that describes the use of STCD (if appropriate). Note: See the section on Sterile Connecting Device for procedural specifics. SOP/job description that describes the responsibilities of the collection device operator. SOP/checklist that describes training. SOP/checklist that describes competency. SOP for validation process. Records to Submit Submit two months of QC data for products collected after validation process. Include products from all collection protocols performed on all devices in use. Include data for each site for which licensure is being requested. Identify facility where QC is performed. Submit relevant validation protocol and data. Complete Form FDA 356h for each product type, for each type of device, by collection site. Include name(s) of the anticoagulant(s) and device(s) that will be used to manufacture the product, and list the manufacturing site(s) that will be collecting the apheresis products. Version 2, January
7 SOP/ Policy # Reference to Prior Submission Items Required for Licensure Attachment # Submit QC sheets that contain the following information: Facility [21 CFR (a)(1)] Device manufacturer and type [21 CFR (a)(2)] Blood Unit Number [21 CFR (c)] Date of collection [21 CFR (a)(1)] Date of testing [21 CFR (a)(7); (a); (a)(1)] Appropriate collection types (single, double, triple, autologous if applicable) Interpretation of results [21 CFR (a)(6); (a)(1); (a)(2)(i)] Interpretation of month Yield [21 CFR ; (b)(7)] Acceptable criteria [21 CFR (d)] Initials [21 CFR (a)(7); (a); (a)(1)] Evidence of review [21 CFR (a)(8; )] Records of calculations [21 CFR (a)(5)] Version 2, January
8 Critical Control Points for Platelets Pheresis Leukocytes Reduced The table below lists some critical control points, by procedure, for Platelets Pheresis Leukocytes Reduced. SOP/Policy # Items Required for Licensure Attachment # SOP CCPs SOP that describes donor suitability needs to describe or include the following: Must meet FDA criteria for allogeneic whole blood donation (21 CFR and ). Persons who have recently ingested medication containing aspirin within 48 hours or Plavix and Ticlid within 14 days may not be suitable donors for Platelets Pheresis. Donation intervals: o If the donation is performed at the same frequency and interval allowed for whole blood, the donor should meet the whole blood suitability criteria. No additional laboratory testing is required for this frequency and interval. o Address the maximum number of procedures a donor can undergo per year and how it will be tracked. o A donor should not generally undergo a total of more than 24 platelet pheresis procedures during a rolling 12 month period. o With intervals of 48 hours between procedures, a donor should not undergo more than two procedures within a 7 day period. o Interval between collection of a double or triple Platelets, Pheresis and any subsequent collection of Platelets, Pheresis should be at least 7 days Platelet count: o If apheresis procedures are to be performed at a greater frequency or at shorter intervals than allowed for whole blood, and if the donor meets the whole blood donor suitability criteria, the following should occur: Blood sample should be drawn from the donor prior to the start of the initial platelet pheresis procedure Version 2, January
9 SOP/Policy # Items Required for Licensure Attachment # o A platelet count should be performed and the results reviewed prior to the donor undergoing each subsequent procedure. Counts obtained after the previous procedure may serve this purpose. The platelet count should be greater than 150,000/uL. Donors whose counts are less than those stated above should be deferred until the counts have returned to normal. Donor needs to meet all additional criteria outlined in the device operator s manual. o Total volume per donation limited to 500 ml or 600 ml if donor weighs >=175 lbs. o Donor who has donated a unit of whole blood, a single unit of Red Blood Cells by apheresis, or a single unit of Red Blood Cells by apheresis with Platelets, Pheresis in the previous 8 weeks is not allowed to donate Platelets, Pheresis, unless the extracorporeal red blood cell volume during the collection is expected to be less than 100 ml. SOP for the consent process should: Describe how and by whom the consent is obtained. Include and provide to the donor: o A description of the procedures to be followed, in language understandable to the donor. o A description of any reasonable foreseeable risks or discomforts that may occur, including side effects of the procedure and the hazards of solutions and/or drugs the donor will receive. o Donation frequency. o Presentation in such a manner that a clear opportunity to refuse is given. o A statement that participation is voluntary and the donor may withdraw his/her consent at any time. o A statement informing the donor of his/her right to ask questions of and discuss the procedure with a physician. o A statement that the donor has reviewed and understands the information provided to Version 2, January
10 SOP/Policy # Items Required for Licensure Attachment # him/her regarding the spread of the AIDS virus by donated blood and plasma. It should also state that if the donor considers him/herself to be at risk for spreading the virus known to cause AIDS, he/she will agree to not donate blood or plasma products for transfusion to another person or further manufacturing. o Long term effects of lymphocyte reduction are unclear. SOP that describes the collection of the product should include: Method of visually inspecting the plasma for hemolysis and the action to take if identified. Donor preparation (e.g., arm prep). Use of STCD (if appropriate). Name and manufacturer of the equipment used for platelet pheresis production. Instructions for management of equipment alarms. SOP that describes the donor deferral procedure on red cell loss should ensure that: Initial donor RBC loss less than 200 ml, no donation or total from initial and second loss less than 200 ml no deferral of donor. Initial donor RBC loss less than 200 ml, second donation more than 200 ml but less than 300 ml total RBC loss donor is eligible 8 weeks after second donation. Initial donor RBC loss more than 200 ml but less than 300 ml donor is eligible 8 weeks after donation. Initial donor RBC loss less than 200 ml, total RBC loss from initial and second donation more than 300 ml donor is eligible 16 weeks after second donation. Initial donor RBC loss more than 300 ml donor is eligible 16 weeks after donation. Version 2, January
11 SOP/Policy # Items Required for Licensure Attachment # SOP that describes the management of donor complications and reactions (adverse events) should address: The documentation for recording these events. The results of investigation and follow-up. The management of a cardiopulmonary emergency including steps for contacting the physician, transport of donor, etc. Medical attendance in the event of donor adverse reactions or physician available within 15 mins. SOP that addresses the Medical Director review of charts should address the following: Time frames for review. Which adverse findings need to be reviewed prior to allowing the donor to return. SOP that describes product acceptability should be consistent with the device operator s manual and include Instructions for management of non-conforming units, to include: o Hematocrit should be performed on the final products containing visibly apparent red blood cells to determine total packed red blood cell volume; if more than 2mL, sample should be attached for compatibility testing. o Directions for management of units that exceed manufacturer s limitations for volume and/or platelet count. Determination of the actual platelet yield of product (volume x platelet count) on every unit. These data should be part of the issue records. SOP that describes handling of the products (components) including storage requirements should address: Specifications for each component to be prepared. Leukocyte reduction methods. Determination of weight/volume. Storage requirements during processing and storage: o Temperature o Agitation Version 2, January
12 SOP/Policy # Items Required for Licensure Attachment # SOP that describes the quarantine of products and disposition of unsuitable products should define: Responsibility for review and authority for disposition of unsuitable products. The process for identification, quarantine, retrieval and recall of unsuitable products. Segregation of unsuitable products. The process to prevent unintended distribution or use of unsuitable products. Release criteria for units later found to be suitable. Record keeping processes and review of such records at appropriate steps. Define documentation that will indicate final disposition of unsuitable units. SOP that describes the labeling process for the product should include the following additional requirements: Expiration date Volume of the product Estimated volume of anticoagulant Residual WBC count SOP that describes packing instructions for shipment and distribution of the product should include: Specification of shipping containers. Specification of the coolant material. Time allowed out of the storage environment. Verification record checks. Shipping records. Labeling of outer box to meet transportation rules. Version 2, January
13 SOP/Policy # Items Required for Licensure Attachment # SOP that describes the quality control on the product should list the method used for QC testing, sample handling requirements (including time limits for sample testing), and ensure: 75% of units tested must contain 3.0x10 11 actual platelet yield (AABB standard: 90% of units tested must meet this requirement). Testing of at least 4 units per month / per site / per product type / per instrument type. ph >6.2 A residual leukocyte count o Single collection -- <5x10 6 per collection or bag, depending on device manufacturer (AABB standard: 95% of units sampled). o Double collection collection < 8.0x10 6 ; components < 5x10 6 o Triple collection collection < 1.2x10 7 ; components < 5x10 6 Percent component retention should be 85% in 95% of the units tested. QC record includes: o Collection site o Name of device manufacturer o Date of collection o Test date o Unit number o Volume of product at time of QC o Actual platelet yield o Percent component retention o Residual WBC o ph o Test interpretation (i.e., acceptable ) o Date/initials of testing tech o Date/initials of reviewer QC review is overseen by qualified staff o Results are tracked. o Trends are identified and failures are investigated. o Corrective action implemented is reviewed for effectiveness. o Instructions are available for appropriate disposition of the unit(s) involved (i.e., failed QC). Version 2, January
14 SOP/Policy # Items Required for Licensure Attachment # SOP that describes the sterility method used during the validation phase should: Follow methodology described in 21 CFR Describe QC of media and storage requirements. Describe test samples, volumes. Describe temperatures and incubation period. Define necessity for repeat testing. Define interpretation of test results. SOP that describes equipment QC / preventive maintenance, including cleaning / calibration, should describe: The required process(es). Personnel assigned to perform the process. When the process is to be performed. Records should be concurrent, reviewed and readily available. What to do when equipment is not in compliance. Validation and Validation Data CCPs Facility instrument information should include: Manufacturer Model Software version Serial # Facility unique ID # (as appropriate) Date installed and placed into service Equipment qualification/validation plan should include: Scope Purpose Responsibility Summary of changes IQ/OQ/PQ requirements and acceptance criteria Validation test cases, if applicable Management discrepancies include a description of whether the discrepancy was included in the acceptance/failure decision or if it was excluded with rationale. Management of products that fail to meet validation release criteria and failure investigation Description of training to include trainer, program, requirements for passing, competency assessment. Version 2, January
15 SOP/Policy # Items Required for Licensure Attachment # During the validation of the procedure: The following determinations should be made for 20 consecutive units (20 singles, 20 doubles, etc.): o Hematocrit or red blood cell count o Platelet count o White blood cell count o ph determination o Total product volume The total number of platelets and the volume of red blood cells obtained from each platelet pheresis should be calculated. During this period, bacterial testing should be performed as described in 21 CFR on outdated units, or on a sample of the product separated at the time of preparation and stored at C for the duration of the dating period. The procedure may be considered established when all operators have been trained and 20 consecutive procedures yield consistently satisfactory products meeting all requirements. Version 2, January
16 Reporting Changes to an Approved BLA Licensed establishments must report changes to their approved application(s) in accordance with 21 CFR Refer to FDA s Guidance for Industry and FDA Review Staff: Collection of Platelets by Automated Methods, December 2007, for guidance. Additional guidance can be located in FDA s Guidance for Industry: Changes to an Approved Application: Biological Products: Human Blood and Blood Components Intended for Transfusion or for Further Manufacture, July Version 2, January
17 Product Submission to CBER for Platelets Pheresis Leukocytes Reduced The table below lists the product submission requirements for platelet pheresis. Items Required for Licensure Prior to submitting products to CBER for testing, verify that the following have occurred: All validation has been completed and reviewed. Two consecutive months of QC records have been completed and reviewed within the last 6 months prior to product submission. There is verification that validation and QC were acceptable. Product Shipment to CBER Call or CBER to schedule shipment: Div. of Hematology Contact Name: CBER ship by: To arrive by: Number of products that will be submitted: Caution: Ensure that shipments will not be received over a weekend or during a holiday. Also, ensure the product will expire Sunday through Thursday after receipt at CBER. Submit: Products (2) from two procedures for single platelets pheresis. Products (4) from two procedures for double platelets pheresis. Products (6) from two procedures for triple platelets pheresis. Ensure that all product tie tags include the following: Identification of the machine (manufacturer) ph Platelet count WBC count Total volume of product Packed red blood cell volume Collection facility identification and address Ensure that the product submitted is labeled in accordance with the facility requirement for shipment of an unlicensed product (i.e., the license number on the product is crossed out). Version 2, January
18 Sterile Connecting Device Using a STCD to pool, mix or remove cellular components represents a change in the product that requires submission and approval of a license application or supplement. The table below lists the critical control points when using STCD. SOP/Policy # Items Required for Licensure Attachment # SOP CCPs A STCD may be used to: Add a new or smaller needle to a blood collection set. Prepare components (add an extra bag, filter, additive solution). Pool blood products. Make aliquots for pediatric use or divided units of WB, RBCs or FFP or Platelets Pheresis. Attach processing solutions (glycerol, saline). Remove samples from blood products for testing. SOP must reflect changes in the assembly of collection and storage containers and in processing steps that involve the STCD for every product made. Records must reflect the date of the sterile connections, the lot numbers of the original containers and needles (and of those being added), the lot numbers of the STCD wafers, the initials of the individual preparing the containers, and a record of each STCD weld inspection and any corrective action taken. Techniques for the detection of leakage or air bubbles and specific instructions for handling the products with faulty welds should be described in SOP. Final product labeling may need to be revised to reflect different product volumes and SOP should describe the minimum volume of split products as well as the expiration date of the final product(s). Procedures for labeling the aliquots or split products should be clearly stated in the SOP. Record keeping should be adequate to permit tracking and recall of all components. Version 2, January
19 Miscellaneous Information Pursuant to FDA regulations, all blood establishments must also maintain the following records. These records do not need to be submitted, but should be available for review during FDA inspections. Records related to instrument and disposable equipment failures and reporting of failures to device manufacturers. Establishments should follow the device operator s manual for corrective action for any adverse or unexpected event, e.g., evidence of product hemolysis. Documentation of observation, standardization and calibration of the automated equipment on a regularly scheduled basis, consistent with the device operator s manual. Documentation of installation, operation and performance qualification tests, as applicable, performed on the automated device prior to implementing routine collections, in accordance with the device operator s manual. Documentation of a thorough investigation, including the conclusions and followup, of any unexplained discrepancy or the failure of a lot or unit to meet any of its specifications. Records of any donor adverse reaction complaints and reports, including results of all investigations and follow-up. References: 21 CFR , , , and Version 2, January
FDA Perspective on Plasma Quality and GMPs
FDA Perspective on Plasma Quality and GMPs Judy Ellen Ciaraldi Food and Drug Administration Division of Blood Components & Devices/OBRR/CBER IPFA/BCA Global Symposium September 23, 2014 Sacramento, California
More informationChanges to an Approved Application: Biological Products: Human Blood and Blood Components Intended for Transfusion or for Further Manufacture
Reprinted from FDA s website by EAS Consulting Group, LLC Changes to an Approved Application: Biological Products: Human Blood and Blood Components Intended for Transfusion or for Further Manufacture Guidance
More informationGuidance for Industry
Guidance for Industry Cooperative Manufacturing Arrangements for Licensed Biologics DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding
More informationGuidance for Industry
Guidance for Industry Cooperative Manufacturing Arrangements for Licensed Biologics Additional copies of this guidance are available from the Office of Communication, Training and Manufacturers Assistance
More informationError Management and BPD Reporting for the Transfusion Service. Mary A Lieb MT(ASCP)SBB, CQA(ASQ) Director, Quality Source Blood Systems,
Error Management and BPD Reporting for the Transfusion Service Mary A Lieb MT(ASCP)SBB, CQA(ASQ) Director, Quality Source Blood Systems, Objectives Define biological product deviation Explain what constitutes
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Page 1 of 5 Home Inspections, Compliance, Enforcement, and Criminal Investigations Enforcement Actions Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations Puget Sound Blood
More informationproducts in conjunction with
FDA reviews red cell transfusion Devices products in conjunction with that collect or process RBCs for transfusion Regulatory pathway: traditional or de novo 510k, PMA Drug solutions for collection, processing
More information6TH EDITION OF FACT-JACIE STANDARDS A QUICK SUMMARY. BHS JACIE Day, 6 March 2015 Eoin McGrath JACIE Operations Manager
6TH EDITION OF FACT-JACIE STANDARDS A QUICK SUMMARY BHS JACIE Day, 6 March 2015 Eoin McGrath JACIE Operations Manager CONTENTS Review process Sources of information Selection of main changes and developments
More informationImplementing 7 Day Platelet Dating with the Platelet PGD Test
Implementing 7 Day Platelet Dating with the Platelet PGD Test The Verax Biomedical Platelet Pan Genera Detection (PGD ) Test is a rapid, qualitative immunoassay for the detection of aerobic and anaerobic
More informationFACT Common Standards for Cellular Therapies, Second Edition. Summary of Changes
FACT Common Standards for Cellular Therapies, Second Edition Summary of Changes This document summarizes major changes made to the Second Edition FACT Common Standards for Cellular Therapies. This summary
More informationDraft Guidance for Industry. This guidance document is for comment purposes only.
Reprinted from FDA s website by EAS Consulting Group, LLC Bacterial Detection Testing by Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for
More informationORC Sponsor-Investigator IDE Checklist
A sponsor-investigator assumes BOTH investigator and sponsor responsibilities as outlined in the FDA Code of Federal Regulations 21CFR812. This means that such investigators have additional responsibilities.
More informationChallenges In Cell Product Labeling, Tracking And Traceability
Challenges In Cell Product Labeling, Tracking And Traceability April 4-5, 2008 Columbus, Ohio Dave Krugh, MT(ASCP)SBB, CLS,CLCP(NCA) Clinical Program Manager, BMT Program Clinical Instructor, Department
More informationPlasma for Fractionation
www.pei.de Plasma for Fractionation Regulatory & Quality Standards in the EU Dr. Sabine Wegehaupt Inspection Services for Biological Medicinal Products IPFA Workshop Stellenbosch December 01-02, 2015 Plasma
More informationValidation plan of the Intercept process for pathogen inactivation in plasma units in Switzerland
Validation plan of the Intercept process for pathogen inactivation in plasma units in Switzerland 1. Introduction... 2 2. Intercept guardbands... 2 3. Prerequisites... 2 4. Pre- validation phase... 3 5.
More informationQuality Program: Supplies and Reagents
Quality Program: Supplies and Reagents J. Wade Atkins, MS, MT(ASCP) SBB, CQA (ASQ) Supervisor, Quality Assurance and Regulatory Affairs Department of Transfusion Medicine, Clinical Center, NIH Disclosures:
More informationIDE Submissions for Devices Used to Manufacture Cell Therapy Products
IDE Submissions for Devices Used to Manufacture Cell Therapy Products Janice Davis-Sproul, MAS Johns Hopkins Medicine 7 th Annual Somatic Cell Therapy Symposium 1 Overview Discuss an investigatorsponsored
More informationFACT Inspector Standards Review Questions 5 th Edition Cord Blood Standards
FACT Inspector Standards Review Questions 5 th Edition Cord Blood Standards Inspector Name: Note: A score of 90% or higher is required to achieve active inspector status. Inspector Techniques 1. As a FACT
More informationReviewers, approvers and executers of this plan are captured in the approval routing tab of this document in IFS.
DOCUMENT NUMBER: 1034722 LOCATION: FT COLLINS/LOVELAND PAGE 1 of 8 1.0 PURPOSE 1.1 The purpose of this Validation Master Plan (VMP) is to identify the validation and testing requirements necessary to qualify
More informationVCU Faculty Held IND and IDE Procedure Handbook
VCU Faculty Held IND and IDE Procedure Handbook Contents A. Introduction... 3 B. Purpose of Institutional Oversight... 3 C. Applicability... 4 D. University Oversight of Clinical Investigations Being Conducted
More informationAssociation of American Railroads Quality Assurance System Evaluation (QASE) Checklist Rev. 1/12/2017
Company: Prepared By: Date: Changes from previous version highlighted in yellow. Paragraph Element Objective Evidence 2.1 Objective of Quality Assurance Program 2.2 Applicability and Scope 2.3 QA Program
More informationUNCONTROLLED COPY WHEN PRINTED
1. PURPOSE 1.1. The purpose of this procedure is to define the steps to be followed and the responsibility for raising a nonconformance/deviation report where material/product or processes do not comply
More informationQUALITY ASSURANCE REQUIREMENTS
SPACE AT MUCKLENEUK CAMPUS PRETORIA QUALITY ASSURANCE REQUIREMENTS SPACE AT MUCKLENEUK CAMPUS, PRETORIA Page 1 1.1 QUALITY ASSURANCE REQUIREMENTS In undertaking the works (including all incidental services
More informationQuality Manual. Quality Manual. Vera Bioscience / Anu Life Sciences. April 2018
Quality Manual Vera Bioscience / Anu Life Sciences April 2018 Page 1 of 15 TABLE OF CONTENTS Quality Manual Page 1. Company Overview 3 2. References 3 3. Exemptions, Alternatives and Variances 3 4. General
More informationDocumenta tion and Records
Documenta tion and Records Page 1 of 30 Training Outcome of the Module: After completing this module, you will be able to: Recognize the importance of procedures Recognize the importance of record keeping
More informationPOST-IRB APPROVAL FDA DRUG (IND) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR312)
POST-IRB APPROVAL FDA DRUG (IND) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR312) Purpose: Investigators who initiate and submit an IND application to the FDA assume the responsibilities of both the
More informationCell Therapy Liaison Meeting, January 27, 2006
Cell Therapy Liaison Meeting, January 27, 2006 Bethesda, MD, Summary Attendees were welcomed by Stephen J. Noga, MD, PhD, ISCT FDA Liaison and the meeting was called to order at 8:15am. HIV and HCV NAT
More informationCode of Practice for Holder of Certificate of Registration as an Importer and Exporter of Pharmaceutical Products
Code of Practice for Holder of Certificate of Registration as an Importer and Exporter of Pharmaceutical Products March 2014 Table of Content INTRODUCTION 3 Section 1: GENERAL RESPONSIBILITIES OF HOLDER
More informationQuality Assurance QA STANDARD OPERATING PROCEDURE FOR FDA or Pharmaceutical Sponsored Audits
Quality Assurance QA 601.01 STANDARD OPERATING PROCEDURE FOR FDA or Pharmaceutical Sponsored Audits Approval: Nancy Paris, MS, FACHE President and CEO 24 May 2017 (Signature and Date) Approval: Frederick
More informationZOLL Document Number: 90E0021 Page 6 of 50 QUALITY SYSTEM MANUAL ZOLL Document Number: 90E0021 Page 7 of 50 1 EXECUTIVE MANAGEMENT APPROVAL... 10 2 INTRODUCTION... 11 3 QUALITY SYSTEM... 12 3.1 QUALITY
More informationSECTION L QUALITY ASSURANCE. 1) designating and managing quality control functions, including:
NT-L1.000 QUALITY ASSURANCE PROGRAM All NADOs shall have a QA Program. Current (2 nd Edition) NT-L1.100 BASIC ELEMENTS SECTION L QUALITY ASSURANCE The QA program shall include, at a minimum: 1) designating
More informationSan Jose, California, USA
Glisland, Inc. San Jose, California, USA http://www.glisland.com Welcome to the Drug GMP World Current Good Manufacturing Practice cgmp ICH Q10 Pharmaceutical Quality System PQS GMP QSR Quality System
More informationFDA Inspections: FDA Inspections: An Overview Overview
FDA Inspections: An Overview Robert Lindblad, MD The EMMES Corporation August 11, 2011 researchcartoons.com Why Inspections? Why Inspections? To evaluate compliance with regulations To establish that an
More informationHot Topics in Drug Product Process Validation: A Reviewer s Perspective
Hot Topics in Drug Product Process Validation: A Reviewer s Perspective Colleen Thomas, Ph.D. Quality Assessment Lead (Acting) FDA/CDER/OPQ/OPF Division of Microbiology Assessment CASSS CMC Strategy Forum
More informationQuality Management Plan for Collections. ISCT Annual Meeting May 24, 2010 Renee Smilee, MT(ASCP) Cell Therapy Manager Moffitt Cancer Center
Quality Management Plan for Collections ISCT Annual Meeting May 24, 2010 Renee Smilee, MT(ASCP) Cell Therapy Manager Moffitt Cancer Center Cost of Quality This is not the price of creating the quality
More informationPIC/S GMP GUIDE FOR BLOOD ESTABLISHMENTS
PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PE 005-2 1 July 2004 PIC/S GMP GUIDE FOR BLOOD ESTABLISHMENTS PIC/S July 2004 Reproduction prohibited for commercial purposes.
More information22 January Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, rm Rockville, MD 20852
22 January 2009 Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, rm. 1061 Rockville, MD 20852 SUBMISSION OF COMMENTS, DOCKET NO. FDA-2008-D-0559 Dear Sir or Madam:
More informationGood manufacturing practices
ORIGINAL PAPER 1AR-10 ISBT Science Series (2009) 4, 6 10 Journal compilation 2009 International Society of Blood Transfusion Good manufacturing practices Blackwell Publishing Ltd A. Ahmed Quality Manager,
More informationMASTER PLANNING FOR VALIDATION
MASTER PLANNING FOR VALIDATION By: Gamal Amer, Ph.D. Principal, Premier Compliance Services, Inc. 1 Process Validation: General Principles and Practices Guidance to industry issued by the FDA in January
More informationGMP On Site Series. GMP Essentials
GMP On Site Series GMP Essentials GMP Basics Objectives 1. State the critical definitions of the pharmaceutical industry. 2. Describe the law as it applies to various critical functions. 3. State the history
More informationRegulatory Schema for Blood Transfusion Microbiotal transplant conference
Regulatory Schema for Blood Transfusion Microbiotal transplant conference Baltimore, 3-4 December 2015 John R. Hess, MD, MPH, FACP, FAAAS Professor of Laboratory Medicine Medical Director, Transfusion
More informationCompassionate Use Navigator Information for Physicians
Compassionate Use Navigator Information for Physicians Contact: Elena Gerasimov, Program Director, Elena@kidsvcancer.org. As a physician, you must have wished there would be more treatment options for
More informationRecent FDA Inspection Findings and Trends
Jan-09 Feb-09 Mar-09 Apr-09 May-09 Jun-09 Jul-09 Aug-09 Sep-09 Oct-09 Nov-09 Dec-09 Jan-10 Feb-10 Mar-10 Apr-10 May-10 Jun-10 Jul-10 Aug-10 Sep-10 Oct-10 Nov-10 Dec-10 Jan-11 Feb-11 Mar-11 Apr-11 May-11
More informationApheresis M. Flores, BSN, RN, HP (ASCP)
Apheresis M. Flores, BSN, RN, HP (ASCP) Objectives: 1. Discuss Apheresis and key concepts 2. Discuss : Cell Collection Extracorporeal Photopheresis (ECP) 1 What is Apheresis? Apheresis: Greek word meaning
More informationCommon AABB Assessment Findings
Common AABB Assessment Findings Linda Sigg, MT(ASCP)SBB, CQA(ASQ) Staff Lead Assessor, Accreditation and Quality AABB Southeastern Area Blood Bankers Association Annual Meeting March 4-5, 2009 Introduction
More informationMarch 9, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852
701 Pennsylvania Avenue, NW Suite 800 Washington, D.C. 20004 2654 Tel: 202 783 8700 Fax: 202 783 8750 www.advamed.org March 9, 2015 Division of Dockets Management (HFA-305) Food and Drug Administration
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Home Inspections, Compliance, Enforcement, and Criminal Investigations Enforcement Actions Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations Celltex Therapeutics Corporation
More informationA Life Cycle Approach to Raw Material Qualification for Cell and Gene Therapy Products
A Life Cycle Approach to Raw Material Qualification for Cell and Gene Therapy Products Angela Whatley, Ph.D. Office of Tissues and Advanced Therapies CBER/FDA CMC Strategy Forum on Cell & Gene Therapies
More informationStarting from Scratch: Experiences with a Focused Apheresis Service
Starting from Scratch: Experiences with a Focused Apheresis Service University of Virginia Tamila Kindwall-Keller, DO, MS September 21, 2018 Disclosures Medical Monitor for BMT CTN 1301 Back Up Medical
More informationWARNING LETTER AUG 3, 2016
Ropack, Inc. 8/3/16 Department of Health and Human Services Public Health Service Food and Drug Administration 10903 New Hampshire Avenue White Oak Building 66 Silver Spring, MD 20993 WARNING LETTER AUG
More information11.0 FDA-Regulated Research
11.0 FDA-Regulated Research The HSC evaluates the safety or efficacy of all drugs and devices used in research. Studies involving unapproved or investigational drugs or devices will be reviewed to ensure
More informationUnder this license, you are approved to manufacture aflibercept drug substance intermediate, drug substance, and formulated bulk at
DEPARTMENT OF HEALTH AND HUMAN SERVICES Silver Spring MD 20993 Our STN: BL 125387/0 BLA APPROVAL November 18, 2011 Regeneron Pharmaceuticals, Inc. Attention: Laura Pologe, Ph.D. Associate Director, Regulatory
More informationGuidelines for Process Validation of Pharmaceutical Dosage Forms
Guidelines for Process Validation of Pharmaceutical Dosage Forms Version 2.1 Date issued 21/02/2010 Date of implementation 21/05/2010 31 August 2010 Page 1 of 20 Guidelines for Process Validation of Pharmaceutical
More informationDocument Type: Main Process: Revision Level: Page: POLICY QUALITY ASSURANCE 3 1 of 6 Process Owner Title:
POLICY QUALITY ASSURANCE 3 1 of 6 Process Owner A. SCOPE This document contains requirements for conducting business with Tri Star Metals, LLC and its customers. It is applicable to suppliers that provide
More informationImmunohematology Practicum Objectives - CLS 645
Clinical Laboratory Sciences Department University of Kansas Medical Center Immunohematology Practicum Objectives - CLS 645 The following objectives are to be completed by the student for successful completion
More informationQuality Management. Carlos Bachier, MD
Quality Management Carlos Bachier, MD Goals of Quality Management Ensure credibility of outcomes Improve patient safety and quality of processes Significantly reduce errors Quality Medical and Laboratory
More information11.0 FDA-Regulated Research Research Involving Investigational Drugs and Biologics
11.0 FDA-Regulated Research The IRB evaluates the safety or efficacy of all drugs and devices used in research. Studies involving unapproved or investigational drugs or devices will be reviewed to ensure
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Page 1 of 8 Inspections, Compliance, Enforcement, and Criminal Investigations Lupin Limited 5/7/09 Department of Health and Human Services Public Health Service Food and Drug Administration CENTER FOR
More informationUNCONTROLLED DOCUMENT
Rheem Manufacturing Company Fort Smith, Arkansas Original Release: 4/06/09 Revision Date: 10/25/16 Quality Management System D. Presley 05 1 of 1 Manual Contents A. Johnson 10/25/16 0 Section Title Revision
More informationAsk the FDA and CMS/CLIA
Ask the FDA and CMS/CLIA 2018 AABB Annual Meeting Boston, Massachusetts October 16, 2018 In compliance with ACCME policy, AABB requires the following disclosures to the session audience. The following
More informationAsk the FDA and CMS/CLIA
Ask the FDA and CMS/CLIA 2018 AABB Annual Meeting Boston, Massachusetts October 16, 2018 In compliance with ACCME policy, AABB requires the following disclosures to the session audience. The following
More informationHealth Products and Food Branch Inspectorate
Our Mandate: To manage and deliver a national compliance and enforcement program for blood and donor semen; cells, tissues and organs; drugs (human and veterinary); medical devices and natural health products,
More informationNational Shellfish Sanitation Program (NSSP) Guide for the Control of Molluscan Shellfish: 2017 Revision
PUBLIC HEALTH SERVICE U.S. FOOD AND DRUG ADMINISTRATION OFFICE OF FOOD SAFETY SHELLFISH AND AQUACULTURE POLICY BRANCH 5001 CAMPUS DRIVE COLLEGE PARK, MD 20740-3835 TEL. 240-402-2151/2055/4960 FAX 301-436-2601
More informationVendor Qualification Survey
1200 West 96 th St Minneapolis, MN 55431 Ph: 952-888-7900 Fax: 952-888-2719 Vendor Qualification Survey Vendor Information Company Name: Date: Address: City: Phone Number: email address: Product or Service
More informationSubpart B Organization and Personnel, 21 CFR Responsibilities of the quality control unit.
FDA inspections continue to focus on CGMP violations related to basic GMP controls. A survey of Warning Letters issued in 2013 on CMC (Chemistry / Manufacturing / Controls) violations reveals an emphasis
More informationCHAPTER 10 FACILITIES EVALUATIONS (PRE-AWARD) SURVEYS PART 1 INTRODUCTION
CHAPTER 10 FACILITIES EVALUATIONS (PRE-AWARD) SURVEYS PART 1 INTRODUCTION 10-1 PURPOSE. This section prescribes procedures for conducting an evaluation of the facilities and capabilities of an offeror,
More informationU. S. Department of Energy. Consolidated Audit Program Treatment, Storage and Disposal Facilities. Checklist 1 Quality Assurance Management Systems
U. S. Department of Energy Consolidated Audit Program Treatment, Storage and Disposal Facilities Checklist 1 Quality Assurance Management Systems Revision 1.3 December 2013 Audit ID: Date: Quality Assurance
More informationINS QA Programme Requirements
Specification Date: 20/3/17 INS QA Programme Requirements UNCONTROLLED WHEN PRINTED Author: J Cooch AUTHORISATION Date: 20/3/17 A Brown Owner: J Cooch (Signature) N.B. only required for hard copy If issued
More informationIQPP Plasma Center Audit Report Form and Checklist
IQPP Plasma Center Audit Report Form and Checklist Version 8.1 December 6, 2016 IQPP Plasma Center Audit Report Form Version 8.1 Auditor Plasma Center Address Government Authority Identification PPTA ID#
More informationQuality Assurance in Pharmaceutical and Biotech Industries as Per Regulatory Guidelines
Human Journals Review Article January 2017 Vol.:8, Issue:2 All rights are reserved by Chagi Venkatesh et al. Quality Assurance in Pharmaceutical Biotech Industries as Per Regulatory Guidelines Keywords:
More information11.0 FDA-Regulated Research Research Involving Investigational Drugs and Biologics
11.0 FDA-Regulated Research The IRB evaluates the safety or efficacy of all drugs and devices used in research. Studies involving unapproved or investigational drugs or devices will be reviewed to ensure
More informationSESSION 14. Documentation Requirements and Management for Validation. 30 March Frits Vogt
Validation Services SESSION 14 Documentation Requirements and Management for Validation 30 March 2017 Frits Vogt fritsvogt@valserv.nl Content Documentation Requirements and Management for Validation I.
More informationMEDICAL DEVICES. Autopheresis-C SYSTEM. Virtually cell-free plasma
MEDICAL DEVICES Autopheresis-C SYSTEM Virtually cell-free plasma Your challenge is our concern: safely collect virtually cell-free plasma The Partner of Choice It s comprehensive. Autopheresis-C system.
More informationResearch Study. Comparison of EmCyte GS30-PurePRP II, EmCyte GS60-PurePRP II, Arteriocyte MAGELLAN, Stryker REGENKIT THT, and ECLIPSE PRP
Research Study Comparison of EmCyte GS30-PurePRP II, EmCyte GS60-PurePRP II, Arteriocyte MAGELLAN, Stryker REGENKIT THT, and ECLIPSE PRP Principle Investigator Robert Mandle, PhD Biosciences Research Associates
More informationSTATE OF OHIO DEPARTMENT OF TRANSPORTATION SUPPLEMENT 1074 CONCRETE PIPE CERTIFICATION PROGRAM FEBRUARY 12, 2003
STATE OF OHIO DEPARTMENT OF TRANSPORTATION SUPPLEMENT 1074 CONCRETE PIPE CERTIFICATION PROGRAM FEBRUARY 12, 2003 1074.01 SCOPE 1074.02 PROGRAM OVERVIEW 1074.03 MANUFACTURER CERTIFICATION PROCESS 1074.04
More informationCorrespondence Between ISO 13485:2016 and 21 CFR Part 820 QMS Requirements
Correspondence Between and 21 CFR Part 820 QMS Requirements 10411 Corporate Drive, Suite 102, Pleasant Prairie, WI 53158 262.842.1250 262.842.1240 info@rcainc.com rcainc.com 2 4 Quality Management System
More informationGLOBAL HEALTH SUPPLY CHAIN QUALITY ASSURANCE QA.APP.GEN-52 Laboratory Commodities and Consumables: Supplier Technical Questionnaire
GLOBAL HEALTH SUPPLY CHAIN QUALITY ASSURANCE Laboratory Commodities and Consumables: Supplier Technical Questionnaire This questionnaire is used to collect information from offerors of Laboratory Commodities
More informationISBT 128 Implementation Experience
ISBT 128 Implementation Experience U. S. Army Kendrick Memorial Blood Center and Eisenhower Army Medical Center Fort Gordon, Georgia Josie Pippert MT(ASCP) Sarah Dailey MT(ASCP) Validation Protocol Army
More informationRegulatory considerations for manufacturing and testing of investigational chimeric antigen receptor (CAR) T-cell products
Regulatory considerations for manufacturing and testing of investigational chimeric antigen receptor (CAR) T-cell products Xiaobin Victor Lu Product Reviewer Gene Therapies Branch DCGT/OCTGT/CBER/FDA MEASUREMENT
More informationAllergy Laboratories, Inc. 10/4/13
Allergy Laboratories, Inc. 10/4/13 SEP 04, 2013 Department of Health and Human Services Public Health Service Food and Drug Administration Office of Regulatory Affairs 12420 Parklawn Drive ELEM-2152 Rockville,
More informationGMPs: Distribution Centers
SkillsPlus International Inc. The On-Site Series GMPs: Distribution Centers Learn to apply the GMP regulations as they relate to distribution center operations! FDA Past, Present, and Future and opener
More informationContents. Contents (13) 1 Production (23)
1 Production (23) 1.A Sanitation (27) 1.A.1 Organisational prerequisites (27) 1.A.2 Sources of contamination (28) 1.A.3 Responsibilities and implementation (29) 1.B Personnel hygiene (31) 1.B.1 Clothing
More informationAAMI Quality Systems White Paper
AAMI s White Paper Comparison of 21 CFR Part 820 to ISO 13485:2016 February 2017, Updated February 2018 AUTHORS Seb Clerkin, GMP Advisory Services Nicola Martin, Owner, Nicola Martin Consulting Jack Ward,
More informationCompliance Program Guidance Manual Chapter 42 Blood and Blood Products
Compliance Program Guidance Manual Chapter 42 Blood and Blood Products Inspection of Licensed In-Vitro Diagnostic (IVD) Devices Regulated by CBER - 7342.008 Implementation Date: October 1, 2012 PRODUCT
More informationEffective Management and Operations of GXP Laboratories
Effective Management and Operations of GXP Laboratories Course Objective: Upon completion of this course, attendees involved in establishing and assuring that Good Laboratory / Good Manufacturing Practice
More informationFacility and Equipment Maintenance
Facility and Equipment Maintenance Deborah L. Griffin Manager, Quality Assurance for Cellular Therapies Hillman Cancer Center University of Pittsburgh Cancer Institute University of Pittsburgh Medical
More informationSummary of TL 9000 R4.0 Requirements Beyond ISO 9001:2000
This summary identifies the additional TL 9000 Release 4.0 requirements beyond those stated in ISO 9001:2000. See the TL 9000 R4.0 Handbook for the actual TL 9000 R4.0 requirements. ISO 9001:2000 section
More informationControlled Environment Commissioning and Qualification Using a Phased Approach to meet schedule demands
Controlled Environment Commissioning and Qualification Using a Phased Approach to meet schedule demands Michael Marino, Sr. QE Effectively Integrating C&Q with Construction & Startup Activities Setting
More informationPART 610 GENERAL BIOLOGICAL PRODUCTS STANDARDS. Subpart A Release Requirements. 21 CFR Ch. I ( Edition) Subpart G Labeling Standards
Pt. 610 and that are licensed under section 351 of the Public Health Service Act, as well as licensed biological products used in the manufacture of a licensed device, must register and list following
More informationHACCP audit checklist
Requirement HACCP audit checklist Prerequisite Program Management Commitment 1. Senior management ensures that the responsibilities and authorities are defined and communicated within the company Internal
More informationISO 9001 PMA and 14 CFR 21 QUALITY POLICIES HANDBOOK
ISO 9001 PMA and 14 CFR 21 QUALITY POLICIES HANDBOOK Origination Date: XXXX Document Identifier: Date: Document Revision: QMS-00 QMS Quality Policies Handbook Latest Revision Date Orig Abstract: This quality
More informationEstablished Conditions: Reportable CMC Changes for Approved Drug and Biologic Products Guidance for Industry
Established Conditions: Reportable CMC Changes for Approved Drug and Biologic Products Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments
More informationSupplier Quality Requirements Manual AEC-300
Page 1 of 12 Supplier Quality Requirements Manual AEC-300 Page 2 of 12 Revision History Rev. Level Section Description DCN Date NC ALL Initial Release DCN-0094 2010-02-24 A 1 Paragraph 16: Software Control
More informationOverview of Regulatory Requirements for API and Formulations
Overview of Regulatory Requirements for API and Formulations Sangeeta Sardesai 4-Dec-2010 Definition - Regulatory Requirement The restrictions, licenses, and laws applicable to a product or business, imposed
More informationAERO GEAR, INC. SUPPLIER QUALITY MANUAL
AERO GEAR, INC. SUPPLIER QUALITY MANUAL REVISION HISTORY REVISION EFFECTIVE DATE SUMMARY OF CHANGES A 30-JAN-1998 Original Issue B 17-OCT-2002 Added note re: subcontractors may not subcontract to another
More informationOffice for Human Subject Protection. University of Rochester
POLICY 1. Purpose Outline the responsibilities and regulatory requirements when conducting human subject research that involves the use of drugs, agents, biological products, or nutritional products (e.g.,
More informationApproved Supplier Guidance
Approved Supplier Guidance Administrative Office: 2420 W. R. Larson Rd. San Antonio, Texas 78261 (210) 384-3484 FAX (830) 438-2309 D&D Machinery and Sales Inc. Approval by: Original copy retained in D&D
More informationc) Have personnel been appointed to supervise the production operations across all shifts in order to ensure the product quality?
Factory s Quality Assurance Ability 1 Responsibilities and Resources 1.1 Responsibilities a) Have the responsibilities and interrelation of various personnel involved in quality activities been defined?
More informationReporting Deviations of Biological Products and HCT/Ps. Ellen Areman Senior Consultant Biologics Consulting Group, Inc.
Reporting Deviations of Biological Products and HCT/Ps Ellen Areman Senior Consultant Biologics Consulting Group, Inc. Relevant Legislation Public Health Service (PHS) Act Regulates biological products
More informationBrumund Foundry Inc.
QUALITY ASSURANCE 1st TIER MANUAL Brumund Foundry Inc. 4400 West Carroll Ave. Chicago, IL 773-287-9250 PER ANSI/ASQC Q9002-1994 Page 1 of 7 THE PRESIDENT HAS DIRECTED THAT THE FOLLOWING POLICIES BE IMPLEMENTED
More information